CASE REPORT

Macrophage Activation Syndrome in a Child with Juvenile Idiopathic Arthritis Secondary to SARS-CoV-2

Hacer Akturk MD,1 Murat Tanyildiz MD,2 Fatih Erbey MD,3 Mehmet Tasdemir MD,4 Aydin Celikyurt MD,5 Emel Gonen MD,6 and Ilmay Bilge MD,7

1Department of Pediatrics, Pediatric Infectious Disease Unit, Koc University Hospital, Istanbul, Turkey
2Department of Pediatrics, Pediatric Intensive Care Unit, Koc University Hospital, Istanbul, Turkey
3Department of Pediatrics, Pediatric Hematology & Oncology Unit, Koc University Hospital, Istanbul, Turkey
4Department of Pediatrics, Pediatric Nephrology Unit, Koc University Hospital, Istanbul, Turkey
5Department of Pediatrics, Koc University Hospital, Istanbul, Turkey
6Department of Orthopedics, Koc University Hospital, Istanbul, Turkey
7Department of Pediatrics, Pediatric Rheumatology Unit, Koc University Hospital, Istanbul, Turkey

Correspondence: Hacer Akturk, Department of Pediatrics, Pediatric Infectious Disease Unit, Koc University Hospital, Davutpaşa Caddesi No: 4, 34010 Topkapi, Istanbul, Turkey. Tel: +90 850 250 8 250. E-mail <hacergunakturk@gmail.com>.

ABSTRACT

Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic affecting many countries and millions of people. Physicians have encountered some rare and challenging cases related to SARS-CoV-2, a novel virus with still many unknowns. In order to share our experience of a such clinical picture, we present here a child with SARS-CoV-2-induced macrophage activation syndrome in the setting of juvenile idiopathic arthritis.

KEYWORDS: severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), macrophage activation syndrome (MAS), secondary haemophagocytic lymphohistocytosis (sHLH), juvenile idiopathic arthritis (JIA)

INTRODUCTION

The pandemic of coronavirus disease-19 (COVID-19), caused by a new coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused significant morbidity and mortality worldwide [1]. An immune-mediated hyper-inflammation in lungs seems to play an important role in development of acute respiratory distress syndrome, the main reason for morbidity and mortality in COVID-19 [2]. Some laboratory parameters, highly
suggestive of macrophage activation syndrome (MAS)/secondary haemophagocytic lymphohistiocytosis (sHLH) are also elevated in a subgroup of severe COVID-19 pneumonia cases. In those patients, a mimicry of autoimmune diseases may be seen including fever, arthralgia, myocarditis, cytopenias, coagulopathy and a cytokine storm similar to MAS [3].

Secondary haemophagocytic lymphohistiocytosis occurs as a result of an exaggerated immunological reaction caused by different inciting conditions like infection, malignity or autoimmune diseases. MAS, as a form of sHLH, is usually associated with autoimmune rheumatic disorders. It develops in approximately 7% of patients with juvenile idiopathic arthritis (JIA) [4].

A broad clinical spectrum affecting different organ systems may be seen over the course of COVID-19. Different clinical profiles may lead to diagnostic and therapeutic dilemmas in some complicated and overlapping conditions. Here, we present such a case: a child who developed MAS during in-hospital treatment of presumed septic arthritis with a differential diagnosis of JIA, and turned out to be SARS-CoV-2 positive.

**CASE REPORT**

A 10-year-old boy had suffered from right ankle pain, swelling and limping. After antibiotic therapy in another hospital, his complaints had partially resolved. Six weeks after the operation, he was admitted to our hospital with recurrence of pain, swelling of the right ankle, fever and refusal to walk. Swelling, redness, warmth and pain were noticed not only on right ankle but also more manifestly on left knee. Acute phase reactants were increased (Table 1). Magnetic resonance imaging showed findings of arthritis and synovitis on affected joints. Aspiration of synovial fluid revealed 25 500 leukocytes/μl with 86% of neutrophils. Although the overall clinical picture had features indicating a diagnosis of JIA, septic arthritis could not be excluded. Thence, an arthrotomy was performed for drainage and aspiration. No bacterial growth was observed on culture. Pathologic examination revealed chronic synovitis. Intravenous antibiotics was commenced, fever subsided, acute phase reactants decreased. The plan was 4 weeks of antibiotics for presumed septic arthritis, together with arrangement of treatment regarding JIA. On the 10th day of hospitalization, he developed fever without any localizing signs and symptoms. No recurrence of arthralgia/arthritis was observed. Blood and urine cultures remained sterile. Viral serologic tests including Epstein barr virus and cytomegalovirus remained negative. Although there is no contact history, due to ongoing pandemic, a nasopharyngeal swab was taken for testing SARS-CoV-2 PCR on 4th day of fever and found to be positive. Laboratory testing showed newly developed cytopenias, increased acute phase reactants, transaminases and triglyceride levels (Table 1). Bone marrow aspiration revealed abundant hemophagocytosis (Fig. 1). Based on these findings, the patient was diagnosed as MAS in the setting of JIA, secondary to SARS-CoV-2 infection. Thorax computed tomography, echocardiography and cardiac enzymes were normal. There were no signs and symptoms related to involvement of gastrointestinal, cutaneous and cardiovascular system. Favipiravir (loading dose: 1600 mg twice daily, maintenance dose: 600 mg twice daily) was commenced for 5 days due to SARS-CoV-2 positivity in a child with MAS. For the treatment of MAS, 1 g/kg/day intravenous immunoglobulin and plasma exchange were administered one after the other for 5 days and 10 mg/m²/day dexamethasone was started. The patient’s condition improved and all abnormal laboratory parameters returned to normal levels. Steroid treatment was continued as oral methylprednisolone and methotrexate was planned as next step in the treatment of JIA.

**DISCUSSION**

Macrophage activation syndrome may be the first manifestation of sJIA, but it may also be seen during the course of an established JIA [5]. Viral infections are known triggers of MAS [5–7]. They can also exacerbate an episode of MAS in patients with known autoimmune diseases [6, 7]. Similarly, we believe that our patient with JIA has experienced a MAS episode, triggered by a viral infection, namely SARS-CoV-2.

A hyper-inflammatory state is known to occur in some COVID-19 patients. An exaggerated immune response resembling MAS/sHLH exacerbates the
condition, which may end with mortality [8]. In COVID-19, this picture generally develops in conjunction with severe lung affection [2]. The patients with cytokine storm also have a severe COVID-19 pneumonia. This is somewhat different from the classic MAS associated with sJIA like settings, in which clinical manifestations generally occur outside the lungs. According to the 2016 MAS classification criteria, our case was diagnosed as MAS due to presence of fever, pancytopenia, increased transaminases, hyperferritinemia, low fibrinogen/high triglyceride levels and presence of hemophagocytosis [9]. He had no lung involvement and was in a relatively good condition throughout the course of the disease, unlike to what has been observed in cytokine storm related to COVID-19 pneumonia.

Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory condition associated with COVID-19. Although MAS and MIS-C have some features in common, they had also some distinct clinical and immunological characteristics [10, 11]. MIS-C has been hypothesized as an immune-mediated postinfectious process to SARS-CoV-2, because the majority of patients have positive SARS-CoV-2 antibody, implying at least a duration of 1–2 weeks between acute infection and onset of MIS-C [11]. Klocperk et al. [12] described a child with a history of JIA who developed a feverish disease with multisystem involvement and systemic inflammation related to SARS-CoV-2 infection. On contrary to our patient, this patient had severe gastrointestinal, cardiac and neurological involvement, a worse clinical status, seldom hemophagocytosis in the bone marrow, a lesser degree of increase in ferritin levels (577 μg/l), and virus-specific IgG positivity together with SARS-CoV-2 PCR positivity. Cardiac involvement, mucocutaneous changes and

### Table 1. Laboratory test results of the patient

| Laboratory tests                                      | On admission | On the day of diagnosis of MAS |
|-------------------------------------------------------|--------------|-------------------------------|
| Leukocyte                                             | 16 080 cells/mm³ | 1750 cells/mm³                |
| Neutrophil                                            | 11 700 cells/mm³ | 1100 cells/mm³                |
| Lymphocytes                                           | 2400 cells/mm³  | 500 cells/mm³                 |
| Hemoglobin                                            | 10.5 g/dl     | 7.4 g/dl                      |
| Platelets                                             | 355 000 cells/mm³ | 75 000 cells/mm³              |
| CRP (N: <5 mg/dl)                                     | 192 mg/l      | 93 mg/dl                      |
| ESR                                                   | 51 mm/h       | 41 mm/h                       |
| Procalcitonin                                         | 3.6 ng/ml     | 57 ng/ml                      |
| Ferritin (N: 12–80 ng/ml)                             | –             | 6980 ng/ml                    |
| IL-6 (N: 1.5–7 pg/ml)                                 | –             | 23.6 pg/ml                    |
| D dimer (N: <500 μg/l)                                | –             | >4000 μg/l                    |
| Fibrinogen                                            | –             | 212 mg/dl                     |
| Triglyceride                                          | –             | 174 mg/dl                     |
| Alanine aminotransferase (N: <39 U/L)                 | 21 U/l        | 145 U/l                       |
| Aspartate aminotransferase (N: <52 U/L)               | 17 U/l        | 141 U/l                       |
| Lactate dehydrogenase (N: 120–300 U/L)               | –             | 696 U/l                       |

Fig. 1. Hemophagocytosis in bone marrow aspirate of the patient.
gastrointestinal symptoms, are reported to be characteristic features of MIS-C rather than MAS [13]. Ferritin levels are found to be significantly higher in patients with MAS compared with MIS-C [11]. Thus, as the authors state, the patient developed a clinical picture compatible with MIS-C [12]. There is neither previous history of COVID-19 exposure nor positive SARS-CoV-2 serology in our patient. He had no signs and symptoms of gastrointestinal, cardiovascular and/or mucocutaneous involvement. His clinical picture, as detailed previously, was compatible with a MAS episode rather than MIS-C.

Since there are conflicting evidence and recommendation surrounding high dose corticosteroid use especially in the early acute phase of COVID-19 infection, high-dose steroid was not used in this case [14]. We made an immunomodulatory treatment plan so-called zipper method, which was previously used in the treatment of other immune-mediated diseases [15]. We think that early initiation of a comprehensive immunomodulatory treatment has helped to achieve a total clinical and laboratory response in a short time.

Small number of children with JIA have been reported to be infected with SARS-CoV-2, and in general low frequency of severe disease complications have been observed [16, 17]. To our knowledge, this is the first case of SARS-CoV-2 induced MAS in the setting of JIA. The course of diagnosis and treatment was compelling due to many unknowns about this novel virus. It seems that SARS-CoV-2 has triggered a hyperinflammatory state in a backdrop of an autoimmune disease. SARS-CoV-2 screening may be considered in flares of autoimmune diseases. We need guidance of accumulating experience and evidence regarding immunomodulatory and antiviral treatment options in such cases.

**CONFLICT OF INTEREST**

The authors have no example conflicts of interests to disclose.

Informed consent was received from the legal guardians of the child.

**REFERENCES**

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579:265–9.
2. McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;19:102537.
3. González-Gay MA, Mayo J, Castañeda S, et al. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Expert Opin Biol Ther 2020;20:717–23.
4. Lin CI, Yu HH, Lee JH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 2012;31:1223–30.
5. Ravelli A, Davi S, Minoia F, et al. Macrophage activation syndrome. Hematol Oncol Clin North Am 2015;29:927–41.
6. Russo RA, Rosenzweig SD, Katsicas MM. Hepatitis A-associated Macrophage Activation Syndrome in children with Systemic Juvenile Idiopathic Arthritis: report of 2 cases. J Rheumatol 2008;35:166–8.
7. McPeake JR, Hirst WJ, Brind MA, et al. Hepatitis A causing a second episode of virus-associated haemophagocytic lymphohistiocytosis in a patient with Still’s disease. J Med Virol 1993;39:173–5.
8. England JT, Abdulla A, Biggs CM, et al. Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes. Blood Rev 2021;45:100707.
9. Henderson LA, Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Paediatr Drugs 2020;22:29–44.
10. Poniecka A, Smolewska E. A fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children—literature review based on two case reports. Reumatologia 2021;59:47–57.
11. Lee PY, Day-Lewis M, Henderson LA, Friedman KG, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest 2020;130:5942–50.
12. Klocperk A, Parackova Z, Dissou J, et al. Case report: systemic inflammatory response and fast recovery in a pediatric patient with COVID-19. Front Immunol 2020;11:1665.
13. Haslak F, Yıldız M, Adrovic A, et al. A recently explored aspect of the iceberg named COVID-19: multisystem inflammatory syndrome in children (MIS-C). Turk Arch Pediatr 2021;56:3–9.
14. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473–5.
15. Kesici S, Tanyıldız M, Yetimakman F, et al. A novel treatment strategy for severe Guillain-Barré
16. Yildiz M, Haslak F, Adrovic A, et al. The frequency and clinical course of COVID-19 infection in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2020;38:1271–2.

17. Ferraccioli ES, Gremese E, Ferraccioli G. Morbidity and mortality from COVID-19 are not increased among children or patients with autoimmune rheumatic disease-possible immunologic rationale: comment on the article by Henderson. Arthritis Rheumatol 2020;72:1772–4.